Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Gram-Negative Multidrug Resistant Pathogen and Its Treatment
share announcement

Gram-Negative Multidrug Resistant Pathogen and Its Treatment

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1473

Special Issue Editor

Dr. Ramón Pérez-Tanoira

E-Mail Website
Guest Editor
1. Department of Microbiology, Hospital Universitario Príncipe de Asturias, 28805 Madrid, Spain
2. Department of Biomedicine and Biotechnology, Universidad de Alcalá, 28801 Alcalá de Henares, Spain
Interests: antimicrobial properties; biofilm; carbapenemase-producing Enterobacteriaceae; multidrug-resistant Pseudomonas aeruginosa; extensively drug-resistant Pseudomonas aeruginosa; gram-negative bacteria; antibiotic multidrug resistance; antibacterial potential; biofilm inhibition; Methicillin-resistant Staphylococcus aureus
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the COVID-19 pandemic, the emergence of extremely resistant microorganisms and an increase in the incidence of carbapenem resistance were documented, possibly related to the increased use of broad-spectrum antibiotics in patients with COVID-19. At the same time, an increase in the rate of device-associated infections in intensive care units has been observed. The rapid global spread of bacteria that have acquired new resistance mechanisms is one of the greatest threats to global health today, causing infections that are impossible to treat. The World Health Organization (WHO) has declared antimicrobial resistance (AMR) among the top 10 threats to global health. The clinical development of new antimicrobials is exhausted, and very few of these are innovative.

The spread of carbapenemase-producing Enterobacteriaceae (CFE), multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Pseudomonas aeruginosa are a global health problem due to their ease of transmission and difficulty of treatment. Nosocomial infections associated with these Gram-negative bacteria have high morbidity and mortality rates, usually occurring in immunocompromised patients and those with multiple comorbidities and undergoing diagnostic-therapeutic procedures and prolonged hospital stays. These bacteria have an outstanding capacity to be selected and to propagate antimicrobial resistance in vivo. For all these reasons, the development of new antibiotics is a top priority.

Dr. Ramón Pérez-Tanoira
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • carbapenemase-producing Enterobacteriaceae
  • multidrug-resistant Pseudomonas aeruginosa
  • extensively drug-resistant Pseudomonas aeruginosa
  • gram-negative bacteria
  • multidrug-resistant
  • antibiotic resistance
  • extended-spectrum beta-lactamase
  • antibacterial potential
  • biofilm inhibition
  • quorum sensing

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 304 KiB  
Article
The Antimicrobial Resistance (AMR) Rates of Enterobacterales in a Rural Hospital from the Eastern Region, Ghana: A Retrospective Study, 2022
by Laura Seijas-Pereda, Carlos Rescalvo-Casas, Marcos Hernando-Gozalo, Vida Angmorkie-Eshun, Eunice Agyei, Vivian Adu-Gyamfi, Isaac Sarsah, Maite Alfonso-Romero, Juan Cuadros-González, Juan Soliveri-de Carranza and Ramón Pérez-Tanoira
Antibiotics 2023, 12(8), 1321; https://doi.org/10.3390/antibiotics12081321 - 16 Aug 2023
Cited by 1 | Viewed by 1141
Abstract
Low- and middle-income countries bear a disproportionate burden of antimicrobial resistance and often lack adequate surveillance due to a paucity of microbiological studies. In this 2022 study, our goal was to contribute to a more precise antimicrobial treatment by understanding the prevalence of [...] Read more.
Low- and middle-income countries bear a disproportionate burden of antimicrobial resistance and often lack adequate surveillance due to a paucity of microbiological studies. In this 2022 study, our goal was to contribute to a more precise antimicrobial treatment by understanding the prevalence of resistance in a rural environment, promoting antibiotic stewardship, and raising awareness about antimicrobial resistance. We assessed the prevalence of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Enterobacterales in clinical samples from 2905 patients being treated at Saint Dominic’s Hospital, Akwatia, in the countryside of the Eastern Region, Ghana, in the year 2022. To this purpose, the samples were cultured on agar plates prepared in the laboratory using purified Oxoid™ Thermo Scientific™ agar (Thermo Fisher Scientific; Waltham, MA, USA). Cystine Lactose Electrolyte-Deficient (CLED) agar was used for urine samples, while blood agar, chocolate agar, and MacConkey agar were used for the rest of the specimens tested (HVS, blood, BFA, sputum). Antimicrobial susceptibility was determined on site using the disc diffusion method (Kirby-Bauer test). MDR bacteria accounted for more than half (53.7%) of all microorganisms tested for three or more antibiotics and 37.3% of these were XDR. Multivariate regression analysis was performed to identify risk factors associated with acquiring MDR/XDR bacteria. The results showed an increased likelihood of MDR acquisition linked to being male (OR 2.39, p < 0.001 for MDR and OR 1.95, p = 0.027 for XDR), higher age (OR 1.01, p = 0.049 for MDR), non-sputum samples (OR 0.32, p = 0.009 for MDR), and urine samples (OR 7.46, p < 0.001 for XDR). These findings emphasize the urgency for surveillance and control of antimicrobial resistance; to this end, making accurate diagnostics, studying the microorganism in question, and conducting susceptibility testing is of the utmost importance. Full article
(This article belongs to the Special Issue Gram-Negative Multidrug Resistant Pathogen and Its Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop